Amid Rising Popularity of Single-Family Rental and Build-for-Rent Assets, Walker & Dunlop Launches Dedicated Practice Group

The rapidly growing SFR market is estimated at $3.4 trillion, compared to the $3.5 trillion multifamily market

PR Newswire

BETHESDA, Md., Feb. 1, 2021 /PRNewswire/ — Walker & Dunlop, Inc. announced today that it has formed a dedicated team to address the rapidly expanding Single-Family Rental (SFR) and Build-for-Rent (BFR) market. While demand has steadily increased over the past several years, migration patterns related to COVID-19 have accelerated the popularity of SFR and BFR properties. An increasing number of investors are therefore expanding their strategy to include the product, and the BFR sub-segment is playing an emerging role in large scale investors’ portfolios.

The SFR market is estimated at $3.4 trillion, compared to $3.5 trillion for the multifamily market,[1] and growth of this asset class is expected to outpace multifamily, office, retail, storage, and hospitality growth within the next few years. BFR properties, a sub-segment of the SFR market, are purpose-built housing to be operated as single-family rental investments. This increasingly popular concept within the multifamily industry currently makes up as much as ten percent of new homes built. While a relatively new product among investors, national homebuilders, and developers, BFR has become more popular to investors, including traditional multifamily developers. The rapidly growing BFR market is expected to continue expanding, as more residents prefer to rent single-family homes with yards and upscale amenities on a long-term basis.

Walker & Dunlop’s specialty practice group comprises 13 experts strategically positioned throughout the business to finance and sell SFR and BFR communities across the United States. The national team is led by Cliff Carnes, Senior Vice President and Capital Markets Western Region Chief Production Officer, Ted Patch, Chief Production Officer of the company’s Multifamily Finance group, and Kris Mikkelsen, Executive Vice President of Investment Sales.

Carnes commented, “The SFR/BFR space will be a very significant part of the rental market’s growth for years to come. Conventional multifamily properties alone cannot keep pace with demand for housing as the number of renters in the U.S. grows. With market demand continuing to outpace supply, the SFR and BFR space will continue to attract renters, developers, owners, and investment dollars.”

Walker & Dunlop’s dedicated SFR & BFR Practice Group provides expert guidance on construction, bridge lending, permanent financing, structuring equity, and property sales to generate optimal returns and strategic relationships for clients. The team has closed and raised capital for over $872M in this burgeoning sector, has an active pipeline of $1.4 billion, and is active with over fifty groups in the space, ranging from institutional clients, homebuilders, multifamily developers, and individual investors.

To learn more about Walker & Dunlop’s view on the BFR market, including information on lending, capital brokerage, or investment sales opportunities, download our whitepaper here.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 1,000+ professionals in 41 offices across the nation have an unyielding commitment to client satisfaction.

[1] Magnify Capital


Cision View original content to download multimedia:–dunlop-launches-dedicated-practice-group-301218916.html

SOURCE Walker & Dunlop, Inc.

Gilat Awarded Contract with a Potential of Over $50 Million to Supply Wavestream’s Gateway Solid State Power Amplifiers for Low Earth Orbit Constellation

PETAH TIKVA, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its subsidiary Wavestream received an award estimated at more than $50M from a leading satellite operator to support the gateways for a Low Earth Orbit (LEO) broadband satellite constellation. Wavestream has been selected to supply Gateway Solid State Power Amplifiers (SSPAs) for the project.

Wavestream’s Gateway-Class PowerStream 160Ka SSPAs, designed specifically for networks using wide bandwidth uplinks and high order modulation schemes, were selected because of their best-in-class technical performance and their unmatched reliability in harsh environments, best addressing the stringent requirements of Non-Geostationary Satellite Orbit (NGSO) constellations.

“Wavestream has been selected as the vendor of choice to support the delivery of essential Gateways for the Low Earth Orbit satellite program,” said Bob Huffman, Wavestream’s General Manager. “Wavestream’s proven technological advantage, as well as our unmatched production capacity, make us a perfect supplier for the high volume of Ka-band Gateway-class SSPAs required for this constellation.”

About Wavestream

Wavestream, a Gilat subsidiary is the industry leader in the design and manufacture of next generation satellite communications high power transceivers for In Flight Connectivity, Ground Mobility and Gateway markets. Since 2001, we provide system integrators with field-proven, high performance Ka, Ku and X band Solid State Power Amplifiers (SSPAs), Block Upconverters (BUCs), Block Down Converters and Transceivers. We design, manufacture and repair our products in-house and have delivered over 40,000 systems in the past 15 years. Wavestream products provide high quality and reliability under the harshest environmental conditions and we are currently certified to ISO 9001:2008 and AS9100D standards. For further details please visit

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With 30 years of experience, we design and manufacture cutting-edge ground segment equipment, and provide comprehensive solutions and end-to-end services, powered by our innovative technology. Delivering high value competitive solutions, our portfolio comprises of a cloud based VSAT network platform, high-speed modems, high performance on-the-move antennas and high efficiency, high power Solid State Amplifiers (SSPA) and Block Upconverters (BUC).

Gilat’s comprehensive solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense and public safety, all while meeting the most stringent service level requirements. Gilat controlling shareholders are the FIMI Private Equity Funds. For more information, please visit:

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, risks associated with the outbreak and global spread of the coronavirus (COVID-19) pandemic; changes in general economic and business conditions, inability to maintain market acceptance to Gilat’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology and risks associated with Gilat’s international operations and its location in Israel. For additional information regarding these and other risks and uncertainties associated with Gilat’s business, reference is made to Gilat’s reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.


Gilat Satellite Networks
Doreet Oren, Director Corporate Communications
[email protected]

GK Investor and Public Relations
Ehud Helft, Managing Partner
[email protected]

A photo accompanying this announcement is available at

International Private Equity Consortium to Buy DuPont Clean Technologies

PR Newswire

NEW YORK and WILMINGTON, Del. and CHICAGO and RIYADH, Saudi Arabia, Feb. 1, 2021 /PRNewswire/ — An international private equity consortium consisting of BroadPeak Global LP (“BroadPeak Global”), Asia Green Fund (“AGF”) and The Saudi Arabian Industrial Investments Company (“Dussur”) (collectively, the “Group”) announced today that they have signed a definitive agreement whereby the Group will purchase the Clean Technologies business of DuPont de Nemours, Inc. (“DuPont”) (NYSE: DD) for $510 million in cash. As part of the transaction, Tensile Capital Management LP is providing preferred equity financing. The transaction is expected to close in the second quarter of 2021 subject to customary closing conditions and regulatory approvals.

Since first producing sulfuric acid catalyst in 1925, DuPont Clean Technologies has become the global leader in: advanced catalyst and process technologies to produce and regenerate sulfuric acid, hydroprocessing technology to desulfurize motor fuels, alkylation technology to produce clean gasoline and advanced air pollution control systems for refineries and chemical facilities. DuPont Clean Technologies also offers a comprehensive suite of aftermarket services and solutions. The Group and DuPont are working together to execute a seamless transition plan that will serve Clean Technologies and its global customer base both reliably and safely.

Mr. Nadim Qureshi, Co-Founder and Managing Partner of BroadPeak Global, said, “DuPont Clean Technologies is a leader in the sulfuric acid, alkylation and scrubbing sectors, with world-class products and aftermarket services. We are excited to have this mission-critical business in our portfolio. We intend to build on this strong foundation and further expand the business with the support of management and our strategic partners.” “The international makeup of the Group will act as a strong complement to the global operations of this leading platform, and we are eager to work together with our fellow consortium members to drive the business forward,” added Stephen Toy, Co-Founder and Managing Partner of BroadPeak Global LP.

Dr. Bo Bai, Asia Green Fund’s Chairman and CEO, said, “The superior technological suite provided by DuPont Clean Technologies will play an instrumental role in helping countries across the world and particularly Asia Pacific tackle environmental issues, push toward carbon neutrality, reduce pollution from mining, oil refining, and chemical industries and upgrade fuel quality. AGF is excited to partner with a synergistic group of co-investors and a strong management team to further the global green impact of Clean Technologies.”

Dr. Raed Al-Rayes, Dussur’s CEO, said, “The Clean Technologies business established by DuPont has unique, environmentally focused, advanced capabilities that present strong synergies with Saudi Arabia’s strategic industrial sectors. We are excited to partner with a dynamic industrial consortium and help expand the business’s footprint across our region and globally.”

Eli Ben-Shoshan, Global Business Director of DuPont Clean Technologies, and future CEO of the intended independent business, said, “I’m extremely proud of the global capabilities and deep expertise of the DuPont Clean Technologies team. We believe this transaction will further strengthen our extensive global relationships to best serve our customers around the world, and I look forward to working with the consortium members to accelerate our growth.”

Credit Suisse AG Singapore branch provided committed debt financing for the transaction. Deutsche Bank Securities Inc. acted as sole M&A advisor to the Group. Kirkland & Ellis LLP provided legal counsel to the Group, and Shearman & Sterling LLP and Squire Patton Boggs provided legal counsel to Dussur. Centerview Partners LLC served as financial advisor to DuPont, and Ballard Spahr LLP acted as legal counsel to DuPont.

About BroadPeak Global
BroadPeak Global LP (“BroadPeak Global”) is an independent private equity firm dedicated to opportunistic buyouts and special situations transactions in the global industrials, materials and chemicals sectors. BroadPeak Global’s Co-Founders, Stephen Toy and Nadim Qureshi, previously served in various leadership roles at Invesco Private Capital and WL Ross & Co. and share a deep heritage of successfully operating and investing across multiple geographies. BroadPeak Global is headquartered in New York City. Learn more at

About Asia Green Fund
Asia Green Fund (“AGF”) is a private equity firm, with approximately $2.0 billion in assets under management, that specializes in the industrials and business services sectors with a focus on technology-enabled green impact investments. Founded in 2016 as Asia’s pioneer in impact investing, AGF backs talented entrepreneurs and management teams as they commercialize innovative technologies with localized business models, thus generating both attractive financial returns for investors as well as a positive ESG impact on society. AGF’s participation in this transaction is being managed from its Chicago office. Learn more at

About Dussur
The Saudi Arabian Industrial Investments Company (“Dussur”) is a strategic industrial investment firm that aims to deliver maximum developmental impact on the Saudi Arabian economy in line with Saudi Vision 2030. Dussur executes regional and international industrial investments with world-class co-investors, creating value for its partners and shareholders. Learn more at

About Tensile Capital Management
Tensile Capital Management (“Tensile”) is a San Francisco-based investment firm managing $1.6 billion in committed capital through an “evergreen” fund structure. Tensile seeks to generate superior risk-adjusted, after-tax returns through long-term investments in a concentrated portfolio of undervalued public securities and select private businesses. With respect to its private investments, Tensile’s ability to invest throughout the capital structure, flexibility in structuring minority investments and active and collaborative partnerships with management teams and boards of directors can provide unique solutions for business owners. Learn more at

About DuPont
DuPont de Nemours, Inc. (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets, including electronics, transportation, construction, water, health and wellness, food and worker safety. Learn more at and

For further information, please visit or contact [email protected].


Cision View original content:

SOURCE BroadPeak Global


Philadelphia, PA, Feb. 01, 2021 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt 5VS) (OTC: VSBGF) (“VSBLTY”), a leading provider of security and retail marketing technology, is partnering with SYNQ, a Canadian innovative retail security and customer experiential technology company, to co-develop a public safety, security solution for Canadian Tire’s third largest location located in Hillside Mall, Victoria, B.C.

SYNQ will utilize VSBLTY’s state-of-the-art software Vector™ in the Canadian Tire store deployment. This proprietary technology, driven by artificial intelligence and machine learning, provides real time occupancy data that will enable this store to automate functions that are normally performed manually. 

Commenting on the new contract, VSBLTY Co-founder & CEO Jay Hutton said, “We are especially pleased to partner with SYNQ to provide best in class security and operational technology for this location of one of Canada’s premier retailers.”

Justin Young, Dealer/Owner of the Canadian Tire store located in Hillside Mall, Victoria, B.C. explained, “Our motivation for installing this advanced technology is to assure the safety of our customers, our employees and our communities in these unprecedented times. The SYNQ/VSBLTY technology ensures accurate counting off our existing cameras, notifying our management when occupancy approaches our set limits for safe shopping in our store. This bolsters our existing investment in Q-Safely, that allows customers to Queue in their vehicles rather than stand outside our location to maintain ultimate safety and comfort.” 

In addition, this solution is already used by over 2000 other retailer locations in Canada and the USA and has over 1 million users per day.

SYNQ’s CEO Nolan Wheeler added, “VSBLTY is the perfect partner for us to provide the kind of people counting and security technology so needed by retailers to safely remain open while COVID-19 is still a threat to the public.”

VSBLTY also has a strong presence in retail and other venues, including “Smart City” type deployments. The firm’s industry-leading VisionCaptor™ and DataCaptor™ software combine motion graphics and interactive brand messaging with cutting-edge computer vision analytics while providing enhanced customer engagement with audience measurement including customer traffic and demographics.


Investor Relations

CHF Capital Markets

Cathy Hume, CEO, +1-416-868-1079, x251

[email protected]


CONTACT: Linda Rosanio, 609-472-0877 

[email protected]


About VSBLTY (


Headquartered in Philadelphia, VSBLTY (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF) (“VSBLTY”) is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence and machine learning.


About SYNQ

SYNQ is dedicated to driving retail excellence through loss prevention and customer experience solutions. The company’s technology bridges the gap between online conversion by leveraging online technologies and tactics within retail brick and mortal locations. Based in Victoria, BC, SYNQ’s products provide retailers with the ability to mitigate the added costs of online orders, curbside pickup, and general operational costs that online retailers are not exposed to. Take that customer experience and store efficiency advantage tied to customer data and it allows traditional retailers to more strongly compete against online competitors.


Nolan Wheeler, CEO, 1-778-433-SYNQ                                                                                  

[email protected]

[email protected]

Celebrate Game Day with Domino’s®

Score the ultimate touchdown with Domino’s $5.99 mix and match deal

PR Newswire

ANN ARBOR, Mich., Feb. 1, 2021 /PRNewswire/ — Large gatherings and parties may seem like a distant memory, but one thing remains the same: on the biggest game day of the year, football fans from all over the country will take a seat around their respective TVs and enjoy pizza, and Domino’s (NYSE: DPZ) corporate and franchise-owned stores are ready to deliver.

Whether you’re ordering a meal for one or for your entire household, when it comes to delivering a satisfying game day feast, there’s only one play to remember: Domino’s $5.99 mix and match deal. Football fans can please everyone by choosing two or more of the following menu items for just $5.99 each: medium two-topping pizzas, Bread Twists, salads, Marbled Cookie Brownies, Specialty Chicken, Oven Baked Sandwiches, Stuffed Cheesy Bread, eight-piece orders of boneless chicken wings or pasta in a dish*.

“Football’s favorite Sunday is consistently one of Domino’s busiest delivery days of the year,” said Jenny Fouracre, Domino’s spokesperson. “Domino’s corporate and franchise team members prepare for this day, much like the final two football teams battling it out. It takes focus, practice, a great player lineup and extra hustle to come through on game day. Domino’s stores across the country have prepared by staffing up, ordering extra ingredients and practicing the art of precision pizza-making.”

Domino’s is committed to providing a safe, delicious, hot meal the way customers want it – whether via contactless carryout or delivery. Stores across the U.S. also offer Domino’s Carside Delivery™, which gives customers the option of staying in their vehicle while a team member delivers their order to them in the store’s parking lot, making for a convenient, contactless carryout experience.

To view Domino’s full menu and place an order, visit

Domino’s Game Day Stats

  • Domino’s typically sells about 2 million pizzas on football’s biggest game day – about 30% more than on a normal Sunday.
  • The most popular pizza topping for the football event of the year is pepperoni.
  • While Domino’s stores throughout Kansas City and Tampa will see high sales at the beginning of the game, the city of the winning team will likely see higher sales at the end of the night.
  • During last year’s game, Domino’s sold enough pizzas to stretch across about 6,000 football fields.

*Any delivery charge is not a tip paid to your driver. Drivers carry less than $20.

 You must ask for this limited time offer. Delivery charge and tax may apply. Prices, participation, delivery area and charges may vary. 2-item minimum. Handmade Pan Pizza, bone-in wings and bread bowl pasta will be extra. Some crust types, toppings, sauces and premium items may come with an additional charge at participating locations.

About Domino’s Pizza®
Founded in 1960, Domino’s Pizza is the largest pizza company in the world based on retail sales. It ranks among the world’s top restaurant brands with a global enterprise of more than 17,200 stores in over 90 markets. Domino’s had global retail sales of more than $14.3 billion in 2019, with over $7.0 billion in the U.S. and nearly $7.3 billion internationally. In the third quarter of 2020, Domino’s had global retail sales of more than $3.7 billion, with over $1.9 billion in the U.S. and nearly $1.8 billion internationally. Its system is comprised of independent franchise owners who accounted for 98% of Domino’s stores as of the end of the third quarter of 2020. Emphasis on technology innovation helped Domino’s achieve more than half of all global retail sales in 2019 from digital channels. In the U.S., Domino’s generated more than 65% of sales in 2019 via digital channels and has developed several innovative ordering platforms, including those for Google Home, Facebook Messenger, Apple Watch, Amazon Echo, Twitter and more. In 2019, Domino’s announced a partnership with Nuro to further its exploration and testing of autonomous pizza delivery. In mid-2020, Domino’s launched a new way to order contactless carryout nationwide – via Domino’s Carside Delivery™, which customers can choose when placing a prepaid online order.

Order –  
Company Info – 
Media Assets –


Cision View original content to download multimedia:

SOURCE Domino’s Pizza, Inc.

Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP

PR Newswire

SAN MATEO, Calif., Feb. 1, 2021 /PRNewswire/ — Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticated financial institutions, family offices, and leading multinational corporations (strategic investors). PVP III LP’s strategic investors include a who’s who of market leaders around the world in their respective industries, including Pfizer Inc. (NYSE: PFE), Corning Incorporated (NYSE:GLW), W. L. Gore & Associates, Showa Denko K. K. (TYO:4004), Nissan Chemical Corporation (TYO:4021), Nagase & Co., Ltd. (TYO:8012), and LG Technology Ventures, which is the investment vehicle of LG Chem, Ltd. (KRX: 051910).  

As the leading venture capital firm focused on Advanced Materials and Device investing, PVP has an established track record of strong returns and is known by entrepreneurs and corporations globally. PVP also has a reputation for forging deep partnerships with its strategic investors working closely with them on open innovation to identify attractive market opportunities. Building off the success of its first two funds, PVP III LP will continue to focus on investing in start-ups developing breakthrough Advanced Materials and Device innovations while expanding its presence globally.  

Dr. John T. Chen, Managing General Partner of PVP, commented, “We are pleased by the strong interest in PVP III LP from new investors and continued support from our existing LPs and are happy to have closed the new fund despite the current global challenges.”

Dr. Zachariah Jonasson, Managing General Partner of PVP added, “We are excited to be working with both the most innovative multinational corporations and entrepreneurs globally.”

About Phoenix Venture Partners LLC

Phoenix Venture Partners LLC is a leading venture capital firm that invests in and partners with outstanding entrepreneurs to commercialize breakthrough Advanced Materials and Device innovations. PVP’s team has an unparalleled track record of founding, building and investing in successful Advanced Materials start-ups across multiple industries. The firm’s investment strategy is flexible and predicated on assisting entrepreneurs with customer and supply chain partnerships, business development, as well as with strategic and operational support. PVP collaborates with a select ecosystem of forward-looking global corporations on business development and open innovation interests. PVP is based in the Silicon Valley with a satellite office in Seattle, WA.  For additional information please visit our website at or email us at [email protected].


Cision View original content to download multimedia:

SOURCE Phoenix Venture Partners, LLC.

REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021

PR Newswire

ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking place virtually from February 8 through 12, 2021. The oral presentations include interim results from the Phase I/II clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II).

The oral presentations will be presented as follows:

Abstract Title: Comparative systemic and neurologic effectiveness of intravenous and intrathecal AAV9 delivered individually or combined in a murine model of mucopolysaccharidosis type I
Presenter: Lalitha Belur, Ph.D., Assistant Professor Genetics, Cell Bio at University of Minnesota
Date/Time: Monday, February 8, 2021, 10:06 a.m. ET

Abstract Title: Intracisternal administration of AAV9 gene therapies to target the central nervous system
Presenter: Bryan A. Pukenas, M.D., Assistant Professor of Radiology at Hospital of the University of Pennsylvania
Date/Time: Tuesday, February 9, 2021, 11:36 a.m. ET

Abstract Title: RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): Interim results of an ongoing first in human trial
Presenter: Marie-Laure Nevoret, M.D., Senior Clinical Development Lead at REGENXBIO
Date/Time: Thursday, February 11, 2021, 9:42 a.m. ET

The poster presentations will be presented as follows:

Abstract Title: Subretinal injection of RGX-381 to cynomolgus monkeys leads to supraphysiological levels of TPP1 in the eye (poster #24)
Presenter: Nicholas Buss, Ph.D., Senior Director, Preclinical Development at REGENXBIO
Date/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: Intracisternal administration of AAV9 gene therapies to target the central nervous system (poster #207)
Presenter: Bryan A. Pukenas, M.D., Assistant Professor of Radiology at Hospital of the University of Pennsylvania
Date/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: First in-human intracisternal dosing of RGX-111 (adeno-associated virus 9/human α-Liduronidase) for a 20-month-old child with mucopolysaccharidosis type I (MPS I): 1 year follow-up (poster #264)
Presenter: Raymond Wang, M.D., Biochemical Genetics Specialist at CHOC Children’s Hospital
Date/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): A clinical program to address central nervous system manifestations (poster #45)
Presenter: Kirsten Cowley, Director, Clinical Operations at REGENXBIO Inc.
Date/Time: Wednesday, February 10, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: Clinical and numerical presentation of neurocognitive assessments for MPS II patients using the Bayley Scales of Infant Development – version 3 (BSID-III) (poster #34)
Presenter: Yoonjin Cho, Ph.D., Director, Biostatistics at REGENXBIO Inc.
Date/Time: Thursday, February 11, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): Interim results of an ongoing first in human trial (poster #171)
Presenter: Marie-Laure Nevoret, M.D., Senior Clinical Development Lead at REGENXBIO Inc.
Date/Time: Thursday, February 11, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: Characterizing expressive language skills in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective (poster #198)
Presenter: Dawn Phillips, Ph.D., Director, Clinical Scientist, Outcomes Research at REGENXBIO Inc.
Date/Time: Thursday, February 11, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: Characterizing visual function in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective (poster #199)
Presenter: Dawn Phillips, Ph.D., Director, Clinical Scientist, Outcomes Research at REGENXBIO Inc.
Date/Time: Thursday, February 11, 2021, from 2:30 to 3:30 p.m. ET

Abstract Title: New research examines the evolution of data sharing practices in natural history studies and patient registries among patient advocate leaders, industry and academia (poster #LB-12)
Presenter: Vivian Fernandez, Senior Director of Patient Advocacy at REGENXBIO Inc.
Date/Time: Friday, February 12, 2021, from 2:30 to 3:30 p.m. ET


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV® Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.


Tricia Truehart

Investor Relations and Corporate Communications
[email protected]

Brendan Burns, 212-600-1902
[email protected]

David Rosen, 212-600-1902
[email protected]


Cision View original content to download multimedia:


Monarch Mining Reports Resource Increase at its Swanson Property

PR Newswire

  • Updated mineral resource estimate for the Swanson property dated January 22, 2021
  • Indicated resource of 1,945,000 t at 1.82 g/t Au for 113,800 ounces of gold
  • Inferred resource of 116,000 t at 2.76 g/t Au for 10,300 ounces of gold
  • Represents 9% more gold in the Indicated category and 45% more gold in the Inferred category

MONTRÉAL, Feb. 1, 2021 /PRNewswire/ – MONARCH MINING CORPORATION (“Monarch” or the “Corporation“) (TSX: GBAR) is pleased to announce an updated mineral resource estimate for its wholly-owned Swanson project, 65 kilometres northeast of Val-d’Or, Québec.

Monarch owns a 100% interest in the Swanson property, acquired from Agnico Eagle Mines Limited. The property, which consists of one mineral lease and 127 claims covering a total area of 51.26 km², hosts a known gold deposit. Located 65 kilometres from the Beacon mill and 12 kilometres northeast of Barraute, Québec, the property is accessible year-round via Route 367 and a gravel road. The property has a 500-metre ramp down to 80 metres and is crossed by a railway track and a transmission line.

Monarch mandated InnovExplo Inc. of Val-d’Or to update the June 20, 2018, resource estimate prepared for Monarch Gold Corp.  The current resource estimate for Monarch Mining indicates that:

  • Geological and grade continuity are demonstrated for the four gold-bearing zones;
  • The estimated resources are reported for combined constrained pit and underground scenarios;
  • The total Indicated resource stands at 113,800 ounces of gold, corresponding to 1,945,000 t at 1.82 g/t Au;
  • The total Inferred resource stands at 10,300 ounces of gold, corresponding to 116,000 t at 2.76 g/t Au;
  • It is likely that additional diamond drilling at depth would increase the Inferred tonnage and allow some of the Inferred resources to be upgraded to the Indicated category.

The resource area within the deposit measures 500 m along strike, 400 m wide and 500 m deep. The estimate is based on a database of 209 drill holes (146 surface holes and 63 underground holes) and 10,000 assays. Grades were capped at 15 g/t Au for the mineralized zones and 4 g/t Au for the dilution envelope. Capping was applied to raw assays before compositing. The mineral resource was estimated using a minimum cut-off grade for two combined potential extraction scenarios: constrained pit and underground. Cut-off grades of 0.75 g/t Au for constrained pit and 2.40 g/t Au for underground were defined based on a gold price of CA$2,160 and an exchange rate of 1.34 USD/CAD.  The independent and qualified persons for the mineral resource estimate, as defined by NI 43–101, are Christine Beausoleil, P.Geo., and Alain Carrier, P.Geo., of InnovExplo.

Table 1 presents the combined resources (in-pit and underground) by category for the Swanson deposit at the selected cut-off grades.

Area (cut-off grade)

Indicated resource

Inferred resource









In-pit (0.75 g/t Au)







Underground (2.40 g/t Au)














This updated mineral resource results in 9% more gold in the Indicated category and 45% more gold in the Inferred category compared to the 2018 resource estimate. This increase in the resource is primarily due to the higher gold price and the resulting lower calculated cut-off grade.

“With our new company, Monarch Mining, we will continue to define and develop our gold assets in one of the most prolific greenstone belts in the world,” said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. “Our near-surface deposits have the potential to expand into significant economic deposits.”

The technical and scientific content of this press release has been reviewed and approved by Louis Martin, P.Geo., the Corporation’s qualified person under National Instrument 43-101.

About Monarch
Monarch Mining Corporation (TSX: GBAR) is a gold mining, development, and exploration company, focused in the prolific Abitibi mining camp in Canada. The Corporation owns four advanced gold properties including the fully permitted past producing Beaufor Mine, which has produced over 1 million ounces of gold over the last 30 years. Other advanced assets include the Croinor Gold, McKenzie Break and Swanson properties, all located in the vicinity of its wholly owned and fully permitted 750 tpd Beacon Mill.

Forward-Looking Statements
The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch’s actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release.

Cision View original content to download multimedia:

SOURCE Monarch Mining Corporation

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). The first step in the collaboration is focused on designing a phase 2 proof of concept study to treat the pain associated with IBS, with the longer-term goal of conducting the phase 2 study.

Greg Duncan, CEO stated, “We are very excited to be working with Dr. Camilleri, a world-renowned expert in gastrointestinal disorders. This proof-of-concept study is intended to evaluate if IMC-1, our proprietary fixed dose antiviral combination of famciclovir and celecoxib, can play a role in addressing the pain associated with IBS.”

About Virios Therapeutics

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate (“IMC-1”), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.

Jenny Kobin

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Health Consumer Women Managed Care Pharmaceutical Biotechnology



Progressive Care Completes Expansion, Launches COVID-19 Rapid Testing at New Orlando Location

MIAMI, FL, Feb. 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce that its new 3,700 square foot Orlando pharmacy has now officially opened for business as a potent full-service location that is also expected to act as a growth hub for rapid results viral testing services, Covid-19 vaccinations, and 340B third-party administration contracting.

The move will allow for a dramatic expansion in services of PharmCoRx pharmacy medication therapy and medication adherence management, and Covid-19 rapid testing solution.

The new location sits just minutes from Orlando International Airport, which will facilitate ease of access for international and out-of-state travelers in need of rapid results Covid-19 testing services required prior to departure as well as the administration of Covid-19 vaccinations (when available).

“This is a jump from a small, bare-bones, fringe outpost store to a state-of-the-art, full-sized, robotics-equipped hub in one of our largest markets,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “The addition to our end-market footprint here promises to have a strong impact on the performance of our core pharmacy services business, as well as our testing and 340B operations with new 340B covered entities under contract. We anticipate substantial growth as we continue to ramp up our Orlando operations.”

For more information about Progressive Care, please visit the Company’s website. Connect and stay in touch with us on social media:

Progressive Care Inc.


About Progressive Care Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

Cautionary Statement Regarding Forward-Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:

Carlos Rangel
[email protected]